A new trading day began on Tuesday, with BioXcel Therapeutics Inc (NASDAQ: BTAI) stock price down -5.94% from the previous day of trading, before settling in for the closing price of $2.02. BTAI’s price has ranged from $1.17 to $21.92 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 6.20% over the past five years. Meanwhile, its annual earnings per share averaged 73.84%. With a float of $5.53 million, this company’s outstanding shares have now reached $6.06 million.
Let’s look at the performance matrix of the company that is accounted for 37 employees. In terms of profitability, gross margin is -11.45%, operating margin of -2970.46%, and the pretax margin is -2163.17%.
BioXcel Therapeutics Inc (BTAI) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 8.76%, while institutional ownership is 6.33%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 73.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 53.72% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Here are BioXcel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -13.52, a number that is poised to hit -1.56 in the next quarter and is forecasted to reach -4.62 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc (NASDAQ: BTAI) saw its 5-day average volume 0.49 million, a negative change from its year-to-date volume of 2.3 million. As of the previous 9 days, the stock’s Stochastic %D was 47.75%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 12.90%, which indicates a significant decrease from 36.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.20 in the past 14 days, which was lower than the 0.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.66, while its 200-day Moving Average is $4.59. Nevertheless, the first resistance level for the watch stands at $2.15 in the near term. At $2.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.54. If the price goes on to break the first support level at $1.76, it is likely to go to the next support level at $1.63. Assuming the price breaks the second support level, the third support level stands at $1.37.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
With a market capitalization of 11.51 million, the company has a total of 6,056K Shares Outstanding. Currently, annual sales are 2,270 K while annual income is -59,600 K. The company’s previous quarter sales were 170 K while its latest quarter income was -7,250 K.
